Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Incoming appointee
3 itemsScheduled Appointment DateEffective 1 December 2026
Ishida Toru (石田 徹)
Previous positionDirector, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office
New positionDirector and Senior Executive Officer, Head of Production Headquarters
Nakajima Yoshinori (中嶋 義徳)
Previous positionExecutive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Department
New positionExecutive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Division
Takada Eiichi (高田 英一)
Previous positionExecutive Officer, General Manager of Procurement and Logistics Headquarters and President of Daito Pharmaceuticals America, Inc.
New positionExecutive Officer, General Manager of Procurement Headquarters and President of Daito Pharmaceuticals America, Inc.
Departing officer
3 itemsIshida Toru (石田 徹)Next role stated
Former PositionDirector, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office
New positionDirector and Senior Executive Officer, Head of Production Headquarters
Nakajima Yoshinori (中嶋 義徳)Next role stated
Former PositionExecutive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Department
New positionExecutive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Division
Takada Eiichi (高田 英一)Next role stated
Former PositionExecutive Officer, General Manager of Procurement and Logistics Headquarters and President of Daito Pharmaceuticals America, Inc.
New positionExecutive Officer, General Manager of Procurement Headquarters and President of Daito Pharmaceuticals America, Inc.
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Ishida Toru (石田 徹) will remain as a director. The changes for Nakajima Yoshinori (中嶋 義徳) and Takada Eiichi (高田 英一) are in their roles as executive officers, and their continued service on the Board of Directors is Not disclosed.
Reason for change
In connection with the implementation, effective 1 December 2026, of the organisational restructuring announced in the 14 October 2026 announcement titled “Notice Concerning Organisational Restructuring,” changes to the officers will be made.
Details of organizational changes
The Production Management Department will change to the Production Management Division, and the Procurement and Logistics Headquarters will change to the Procurement Headquarters. The position of Head of the Environmental Safety Office will be discontinued.
| Item | Details |
|---|---|
| Scheduled Appointment Date | Effective 1 December 2026 |
| Name of appointee | Ishida Toru (石田 徹), Nakajima Yoshinori (中嶋 義徳), Takada Eiichi (高田 英一) |
| Appointee's new position | Director and Senior Executive Officer, Head of Production Headquarters, Executive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Division, Executive Officer, General Manager of Procurement Headquarters and President of Daito Pharmaceuticals America, Inc. |
| Appointee's previous position | Director, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office, Executive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Department, Executive Officer, General Manager of Procurement and Logistics Headquarters and President of Daito Pharmaceuticals America, Inc. |
| Name of departing officer | Ishida Toru (石田 徹), Nakajima Yoshinori (中嶋 義徳), Takada Eiichi (高田 英一) |
| Former position of departing officer | Director, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office, Executive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Department, Executive Officer, General Manager of Procurement and Logistics Headquarters and President of Daito Pharmaceuticals America, Inc. |
| New position of departing officer | Director and Senior Executive Officer, Head of Production Headquarters, Executive Officer, Deputy Head of Production Headquarters and General Manager of Production Management Division, Executive Officer, General Manager of Procurement Headquarters and President of Daito Pharmaceuticals America, Inc. |
| Whether the incumbent will remain in office | Ishida Toru (石田 徹) will remain as a director. The changes for Nakajima Yoshinori (中嶋 義徳) and Takada Eiichi (高田 英一) are in their roles as executive officers, and their continued service on the Board of Directors is Not disclosed. |
| Reason for change | In connection with the implementation, effective 1 December 2026, of the organisational restructuring announced in the 14 October 2026 announcement titled “Notice Concerning Organisational Restructuring,” changes to the officers will be made. |
| Details of organizational changes | The Production Management Department will change to the Production Management Division, and the Procurement and Logistics Headquarters will change to the Procurement Headquarters. The position of Head of the Environmental Safety Office will be discontinued. |
Items this document does not state (11)
Resolution dateDate of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is in connection with the implementation, effective 1 December 2026, of the organisational restructuring announced on 14 October 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.